Daniel H Hovelson (D Hovelson)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 2

Top Topics

Acute Kidney Injury

Diffuse Large B Cell Lymphoma

Top Venues

Cancer research communications

NPJ precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Benjamin J Bulen, Nickolay A Khazanov, Daniel H Hovelson, Laura E Lamb, Marc Matrana, Mark E Burkard, Eddy Shih-Hsin Yang, William Jeffery Edenfield, Elizabeth C Dees, Adedayo A Onitilo, Gary L Buchschacher, Alan M Miller, Benjamin M Parsons, Timothy R Wassenaar, Jennifer M Suga, Robert D Siegel, William Irvin, Suresh G Nair, Jennifer N Slim, Jamal Misleh, Jamil Khatri, Gregory A Masters, Sachdev Thomas, Malek M Safa, Daniel M Anderson, Jonathan Mowers, Anna C Dusenbery, Stephanie Drewery, Komal Plouffe, Travis Reeder, Hana Vakil, Lynnae Patrias, Amanda Falzetta, Ryan Hamilton, Kat Kwiatkowski, D Bryan Johnson, Daniel R Rhodes, Scott A Tomlins
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit. Cancer research communications 3 (7) (2023)
Aaron S Mansfield, Zihan Wei, R Mehra, A T Shaw, Christopher H Lieu, Patrick M Forde, Alexander E Drilon, E P Mitchell, J J Wright, N Takebe, E Sharon, Daniel H Hovelson, S Tomlins, J Zeng, K Poorman, N Malik, Robert C Gray, S Li, L M McShane, Lawrence V Rubinstein, David R Patton, P Mickey Williams, S R Hamilton, B A Conley, C L Arteaga, L N Harris, P J O'Dwyer, A P Chen, K T Flaherty
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. NPJ precision oncology 6 (1) (2022)